News

WebMD3mon
FDA Approves New Treatment for Stroke
The treatment, tenecteplase (sold as TNKase), delivers a single five-second IV shot, making it a faster, easier option. TNKase was initially approved in 2000 to reduce the risk of death from acute ...
Hosted on MSN3mon
FDA Approves TNKase To Treat Ischemic Strokes In Adults
The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults. Ischemic strokes ...
GlobalData on MSN3mon
Genentech wins FDA approval for second stroke treatment
Genentech has secured a second marketed stroke therapy after the US Food and Drug Administration (FDA) approved a label ...
Healio3y
Low-dose tenecteplase safe, effective up to 24 hours after ischemic stroke onset
According to the results of a phase 2a trial presented at the International Stroke Conference, low-dose tenecteplase (TNKase, Genentech) was more effective in achieving the primary outcome of ...
Killeen Daily Herald3mon
FDA Approves TNKase for Acute Ischemic Stroke
THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic ...
Yahoo Finance3mon
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
March 03, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase ...